BACKGROUND: Accurate estimation of life expectancy is essential to offering appropriate care to men with early-stage prostate cancer, but mortality risks associated with comorbidity are poorly defined. OBJECTIVE: To determine the effect of age, comorbidity, and tumor risk on other-cause and prostate cancer-specific mortality in men with early-stage disease. DESIGN: Prospective cohort study. SETTING: A nationally representative, population-based cohort. PATIENTS: 3183 men with nonmetastatic prostate cancer at diagnosis. MEASUREMENTS: Baseline self-reported comorbidity (scored as a count of 12 major comorbid conditions), tumor characteristics, initial treatment, and overall and disease-specific mortality through 14 years of follow-up. Survival analyses that accounted for competing risks were performed. RESULTS: Fourteen-year cumulative other-cause mortality rates were 24%, 33%, 46%, and 57% for men with 0, 1, 2, and 3 or more comorbid conditions, respectively. For men diagnosed at age 65 years, subhazard ratios for other-cause mortality among those with 1, 2, or 3 or more comorbid conditions (vs. none) were 1.2 (95% CI, 1.0 to 1.4), 1.7 (CI, 1.4 to 2.0), and 2.4 (CI, 2.0 to 2.8), respectively. Among men with 3 or more comorbid conditions, 10-year other-cause mortality rates were 26%, 40%, and 71% for those aged 60 years or younger, 61 to 74 years, and 75 years or older at diagnosis, respectively. Prostate cancer-specific mortality was minimal in patients with low-risk (3%) and intermediate-risk (7%) disease but appreciable in those with high-risk disease (18%) and did not vary by number of comorbid conditions (10% to 11% in all groups). LIMITATION: Comorbid conditions were self-reported. CONCLUSION: Older men with multiple major comorbid conditions are at high risk for other-cause mortality within 10 years of diagnosis and should consider this information when deciding between conservative management and aggressive treatment for low- or intermediate-risk prostate cancer. PRIMARY FUNDING SOURCE: National Cancer Institute.
BACKGROUND: Accurate estimation of life expectancy is essential to offering appropriate care to men with early-stage prostate cancer, but mortality risks associated with comorbidity are poorly defined. OBJECTIVE: To determine the effect of age, comorbidity, and tumor risk on other-cause and prostate cancer-specific mortality in men with early-stage disease. DESIGN: Prospective cohort study. SETTING: A nationally representative, population-based cohort. PATIENTS: 3183 men with nonmetastatic prostate cancer at diagnosis. MEASUREMENTS: Baseline self-reported comorbidity (scored as a count of 12 major comorbid conditions), tumor characteristics, initial treatment, and overall and disease-specific mortality through 14 years of follow-up. Survival analyses that accounted for competing risks were performed. RESULTS: Fourteen-year cumulative other-cause mortality rates were 24%, 33%, 46%, and 57% for men with 0, 1, 2, and 3 or more comorbid conditions, respectively. For men diagnosed at age 65 years, subhazard ratios for other-cause mortality among those with 1, 2, or 3 or more comorbid conditions (vs. none) were 1.2 (95% CI, 1.0 to 1.4), 1.7 (CI, 1.4 to 2.0), and 2.4 (CI, 2.0 to 2.8), respectively. Among men with 3 or more comorbid conditions, 10-year other-cause mortality rates were 26%, 40%, and 71% for those aged 60 years or younger, 61 to 74 years, and 75 years or older at diagnosis, respectively. Prostate cancer-specific mortality was minimal in patients with low-risk (3%) and intermediate-risk (7%) disease but appreciable in those with high-risk disease (18%) and did not vary by number of comorbid conditions (10% to 11% in all groups). LIMITATION: Comorbid conditions were self-reported. CONCLUSION: Older men with multiple major comorbid conditions are at high risk for other-cause mortality within 10 years of diagnosis and should consider this information when deciding between conservative management and aggressive treatment for low- or intermediate-risk prostate cancer. PRIMARY FUNDING SOURCE: National Cancer Institute.
Authors: A L Potosky; L C Harlan; J L Stanford; F D Gilliland; A S Hamilton; P C Albertsen; J W Eley; J M Liff; D Deapen; R A Stephenson; J Legler; C E Ferrans; J A Talcott; M S Litwin Journal: J Natl Cancer Inst Date: 1999-10-20 Impact factor: 13.506
Authors: Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Hans Garmo; Jennifer R Stark; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson Journal: N Engl J Med Date: 2011-05-05 Impact factor: 91.245
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Helen M Sheriff; Manik R Thogaripally; Gurusher Panjrath; Cherinne Arundel; Qing Zeng; Gregg C Fonarow; Javed Butler; Ross D Fletcher; Charity Morgan; Marc R Blackman; Prakash Deedwania; Thomas E Love; Wilbert S Aronow; Stefan D Anker; Richard M Allman; Ali Ahmed Journal: J Am Med Dir Assoc Date: 2017-05-11 Impact factor: 4.669
Authors: Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson Journal: Urology Date: 2014-09-26 Impact factor: 2.649
Authors: Katharina Boehm; Paolo Dell'Oglio; Zhe Tian; Umberto Capitanio; Felix K H Chun; Derya Tilki; Axel Haferkamp; Fred Saad; Francesco Montorsi; Markus Graefen; Pierre I Karakiewicz Journal: World J Urol Date: 2016-10-28 Impact factor: 4.226
Authors: Matthew Huber; Tezcan Ozrazgat-Baslanti; Paul Thottakkara; Philip A Efron; Robert Feezor; Charles Hobson; Azra Bihorac Journal: Ann Vasc Surg Date: 2015-07-14 Impact factor: 1.466
Authors: Ann S Hamilton; Steven T Fleming; Dian Wang; Michael Goodman; Xiao-Cheng Wu; Jean B Owen; Mary Lo; Alex Ho; Roger T Anderson; Trevor Thompson Journal: Am J Clin Oncol Date: 2016-02 Impact factor: 2.339
Authors: Parth K Modi; Samuel R Kaufman; Tudor Borza; Phyllis Yan; David C Miller; Ted A Skolarus; John M Hollingsworth; Edward C Norton; Vahakn B Shahinian; Brent K Hollenbeck Journal: Cancer Date: 2018-06-15 Impact factor: 6.860